Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317822 | 1.00 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LTA4HARG1KDR | |
| SCHEMBL27777191 | 1.00 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LTA4HARG1KDR | |
| SCHEMBL12726845 | 0.85 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2LTA4HKDR | |
| SCHEMBL25086280 | 0.81 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LTA4HKDR | |
| SCHEMBL27342995 | 0.76 | LTA4H (0.36) | SMN1; SMN2LTA4HKDR | |
| SCHEMBL441486 | 0.74 | GPR119 (0.38) | LTA4HARG1 | |
| SCHEMBL4327148 | 0.74 | DPP4 (0.35) | — | |
| SCHEMBL12935790 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2LTA4H | |
| SCHEMBL357967 | 0.73 | CYP2D6 (0.51) | CYP2D6SMN1; SMN2 | |
| SCHEMBL18502936 | 0.73 | ALOX15 (0.46) | SMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9849136-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9617254-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170081320-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170057932-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| CN-101528717-A | Thiazole and oxazole-substituted arylamides | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | CN | disclosed |
| EP-2091927-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-Roche AG (CH) | 2009-08-26 | — | — | EP | disclosed |
| CN-101479250-A | Tetrazole-substituted arylamides | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | CN | disclosed |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20080132494-A1 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| WO-2008055840-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | P2RX2, P2RX3, TPX2 | CYP2D6 1802/4885SMN1; SMN2 1569/4885LTA4H 1481/4885 |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | CYP2D6 1691/4885SMN1; SMN2 2444/4885LTA4H 907/4885 |
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | CYP2D6 2058/4885SMN1; SMN2 3216/4885LTA4H 1754/4885 |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX1 | CYP2D6 1390/4885SMN1; SMN2 3507/4885LTA4H 1162/4885 |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | P2RX2, P2RX3, TPX2 | CYP2D6 1875/4885SMN1; SMN2 1527/4885LTA4H 1477/4885 |
| US-20170081320-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | CYP2D6 1452/4885SMN1; SMN2 3274/4885LTA4H 687/4885 |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | CYP2D6 1375/4885SMN1; SMN2 3247/4885LTA4H 1100/4885 |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | CYP2D6 1661/4885SMN1; SMN2 3478/4885LTA4H 992/4885 |
| US-20080132494-A1 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX1 | CYP2D6 2266/4885SMN1; SMN2 3301/4885LTA4H 929/4885 |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX5 | CYP2D6 1512/4885SMN1; SMN2 2345/4885LTA4H 799/4885 |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | CYP2D6 1375/4885SMN1; SMN2 3247/4885LTA4H 1100/4885 |
| US-20170057932-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | CYP2D6 1132/4885SMN1; SMN2 3278/4885LTA4H 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.